Home / Market News / $XNCR

$XNCR news and market catalysts

The 20 most recent market catalysts affecting $XNCR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

20 catalysts 4 high impact 13 bullish 1 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Neutral Impact 55
Xencor Insider Sells Shares Worth Over $3 Million
The SEC filing indicates an insider at Xencor, Inc. sold $3,189,435 worth of company shares. While insider selling can sometimes be interpreted negatively as a lack of confidence, …
Nov 9, 2026 Corporate Catalyst Bullish Impact 75
Xencor Provides Clinical Pipeline and R&D Updates
Xencor provided a comprehensive update on its clinical pipeline, highlighting initial positive dose-escalation data for plamotamab in rheumatoid arthritis and a significant 45.5% c…
Nov 9, 2026 Corporate Catalyst Neutral Impact 65
Xencor Announces Initial Plamotamab Data and XmAb657 Study Update
Xencor announced initial dose-escalation data from its Phase 1b clinical study of plamotamab for rheumatoid arthritis and an update on its XmAb657 study. This matters because posit…
Nov 9, 2026 Corporate Catalyst Bullish Impact 85
Positive Phase 3 Results for Elebsiran and Tobevibart Regimen Utilizing Xencor's Xtend™ Technology
Xencor announced overwhelmingly positive Phase 3 results for its elebsiran and tobevibart regimen, which incorporates its proprietary Xtend™ technology. The trial met all primary e…
Nov 4, 2026 Corporate Catalyst Bullish Impact 95
Xencor, Inc. Reports Q3 2026 Financial Results
Xencor, Inc. reported Q3 2026 financial results that dramatically surpassed analyst expectations, with revenue nearly doubling the consensus estimate and a significant swing from a…
Nov 2, 2026 Corporate Catalyst Neutral Impact 75
Analysts Update Price Targets and Ratings for Xencor
On November 2, 2026, multiple financial analysts, including Wells Fargo, RBC Capital Markets, Wedbush, and Truist Financial, raised their price targets and maintained positive rati…
Oct 27, 2026 Corporate Catalyst Neutral Impact 65
Wells Fargo and Barclays Adjust Price Targets for Xencor
Wells Fargo and Barclays have both raised their price targets for Xencor, with Wells Fargo moving from $30 to $44 and Barclays from $35 to $45, while maintaining their Buy ratings.…
Oct 27, 2026 Corporate Catalyst Bullish Impact 65
Analysts Raise Price Targets on Xencor
RBC Capital Markets and Wedbush both substantially increased their price targets for Xencor, from $20 to $43 and $30 to $45 respectively, while reiterating 'Outperform' ratings. Th…
Oct 26, 2026 Corporate Catalyst Bullish Impact 65
Wedbush Adjusts Xencor Price Target to $45
Wedbush Securities has significantly raised its price target for Xencor (XNCR) from $30 to $45, while reiterating an Outperform rating. This positive adjustment is a direct consequ…
Oct 25, 2026 Corporate Catalyst Neutral Impact 75
Xencor Presents Phase 1 Dose Selection Data for XmAb819 in Advanced ccRCC
Xencor presented updated Phase 1 data for XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, at the 2026 ESMO Congress. The key disclosure is the selection of 400 mcg/kg …
Sep 28, 2026 Corporate Catalyst Bullish Impact 65
Xencor shares are trading higher after Truist Securities reiterated the stock with a Buy rating and raised the price target from $27 to $29.
The reiteration of a 'Buy' rating and an increased price target from a reputable financial institution like Truist Securities acts as a strong positive catalyst for Xencor. This si…
Sep 28, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29
Truist Securities analyst Gregory Renza reaffirmed a 'Buy' rating for Xencor (XNCR) and raised the price target from $27 to $29. This action signals a strengthened conviction in th…
Sep 11, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Xencor, Raises Price Target to $35
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Xencor and raised the price target from $27 to $35. This action signals a strengthened positive outlook from a re…
Sep 1, 2026 Corporate Catalyst Bullish Impact 55
Raymond James Maintains Strong Buy on Xencor, Raises Price Target to $46
Raymond James analyst Sean McCutcheon has maintained a 'Strong Buy' rating on Xencor (XNCR) and raised the price target from $40 to $46. This action signals increased confidence fr…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20
RBC Capital's analyst Leonid Timashev has raised the price target for Xencor (XNCR) from $19 to $20 while maintaining an Outperform rating. This action reflects a slightly improved…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Maintains Outperform on Xencor, Raises Price Target to $30
Wedbush analyst David Nierengarten has maintained an 'Outperform' rating on Xencor and raised the price target from $26 to $30. This action signals increased confidence in Xencor's…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Cantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $44
Cantor Fitzgerald analyst Steve Seedhouse has maintained an 'Overweight' rating on Xencor (XNCR) and raised the price target from $43 to $44. This action signals continued confiden…
Aug 5, 2026 Corporate Catalyst Bullish Impact 92
Xencor Q2 EPS $(0.29) Beats $(0.79) Estimate, Sales $51.200M Beat $18.922M Estimate
Xencor announced its Q2 financial results, reporting a loss per share of $(0.29) which significantly beat the analyst estimate of $(0.79). Additionally, the company's sales of $51.…
Jul 29, 2026 Corporate Catalyst Bearish Impact 85
Xencor Announces $105M Settlement From Alexion Over US Ultomiris Royalties In Two $52.5M Payments; Ends US Royalties, Extends Operating Runway Through 2028
This settlement is a major positive for Xencor, providing $105 million in non-dilutive capital, which significantly extends its operating runway through 2028. This reduces immediat…
Jul 17, 2026 Corporate Catalyst Neutral Impact 65
Xencor Announces Phase 1 Study Results For XmAb819 Antibody Accepted For Proffered Paper Oral Presentation At European Society of Medical Oncology October 23-27
Xencor's 8-K filing announces the acceptance of Phase 1 results for its XmAb819 antibody for an oral presentation at the prestigious ESMO conference. This is a positive development…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.